Cargando…

SARS-CoV-2 infection in liver transplant recipients-a single center case series from Romania

Detalles Bibliográficos
Autores principales:	Husar-Sburlan, Ioana-Alexandra, Grigorescu, Raluca Roxana, Radu, Elena Cristina, Tabacelia, Daniela, Florescu, Madalina, Nitu, Florina, Dumitru, Radu, Stanila, Ana, Martiniuc, Alexandru, Boleac, Nicolae, Chirita, Dragos, Popa-Dan, Laura, Stroescu, Cezar, Copca, Narcis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Saturday 25 June: Liver transplantation and hepatobiliary surgery: Clinical aspects
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252406/ http://dx.doi.org/10.1016/S0168-8278(22)01898-0

Ejemplares similares

New approach for hepatocellular carcinoma treatment
por: Tabacelia, Daniela, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine
por: Raszeja-Wyszomirska, Joanna, et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

The impact of COVID-19 on the duration of the liver transplant process in patients presenting for inpatient liver transplant evaluation
por: Cooper, Katherine, et al.
Publicado: (2022)

Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients
por: Rabinowich, Liane, et al.
Publicado: (2022)

Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications
por: Singal, Ashwani, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients
por: Calleri, Alberto, et al.
Publicado: (2022)

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients
por: Herrán, Aitor Odriozola, et al.
Publicado: (2022)

Does m-RNA vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients?
por: Comandini, Ubaldo Visco, et al.
Publicado: (2022)

Predictive factors of antibody response after anti-SARS-CoV-2 vaccine in liver transplant recipients
por: Kounis, Ilias, et al.
Publicado: (2022)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation-a prospective six month follow-up
por: Kirchner, Theresa, et al.
Publicado: (2022)

Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients
por: Mendizabal, Manuel, et al.
Publicado: (2022)

Efficacy and safety of SARS-CoV-2 vaccination in liver transplant recipients
por: Meunier, Lucy, et al.
Publicado: (2022)

Third dose of SARS-COV2 mRNA-vaccine in liver transplant recipients: can it bridge the response gap?
por: Montalbano, Marzia, et al.
Publicado: (2022)

Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome
por: Cohen-Naftaly, Michal, et al.
Publicado: (2022)

Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose.
por: Sempere, Elena Diago, et al.
Publicado: (2022)

Hot topics in therapeutic EUS
por: Tabacelia, Daniela, et al.
Publicado: (2022)

A “Mix and Match” in Hemochromatosis—A Case Report and Literature Focus on the Liver
por: Cobilinschi, Claudia Oana, et al.
Publicado: (2023)

SARS-CoV-2 induces pericyte procoagulant response associated with portal vein microthrombosis and intrapulmonary vascular dilations in fatal COVID-19
por: Lasagni, Alberto, et al.
Publicado: (2022)

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
por: Lawitz, Eric, et al.
Publicado: (2022)

P203 Earlier identification of human immunodeficiency virus and hepatitis C virus in high-risk emergency departments
por: Fenton, J., et al.
Publicado: (2009)

Exposure to the SARS-CoV-2 spike protein in an in vitro model of steatosis enhances hepatocyte oxidative stress: implications for COVID-19 and accelerated disease progression
por: Jacobs, Angus, et al.
Publicado: (2022)

Pregnancy in Patients with Inflammatory Bowel Diseases—A Literature Review
por: Grigorescu, Raluca Roxana, et al.
Publicado: (2023)

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
por: Saha, Supriya K., et al.
Publicado: (2016)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Correlation of liver-to-spleen ratio, lung CT scores, clinical, and laboratory findings of COVID-19 patients with two consecutive CT scans
por: Guler, Ezgi, et al.
Publicado: (2020)

Feasibility and safety of bedside percutaneous biliary drainage in patients with severe cholangitis
por: Gupta, Pankaj, et al.
Publicado: (2020)

Higher frequency of hepatic steatosis at CT among COVID-19-positive patients
por: Medeiros, Augusto Kreling, et al.
Publicado: (2020)

CT of amebic liver abscess: different morphological types with different clinical features
por: Priyadarshi, Rajeev Nayan, et al.
Publicado: (2021)

The natural course of giant paraesophageal hernia and long-term outcomes following conservative management
por: Oude Nijhuis, Renske A B, et al.
Publicado: (2020)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

Impact of thyroid disorders on the incidence of non‐alcoholic fatty liver disease in Germany
por: Labenz, Christian, et al.
Publicado: (2021)

Inhibition of NAE‐dependent protein hyper‐NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease
por: Lee‐Law, Pui Y., et al.
Publicado: (2021)

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iid1a8mlr5of2fg18fkg7qtq6i